UCBJY Quote, Financials, Valuation and Earnings

Celyad Oncology SA has a net margin of -- compared to UCB SA's net margin of --. UCB SA's return on equity of 13.88% beat Celyad Oncology SA's return on equity of --.

UCB SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Celyad Oncology SA has an analysts' consensus of -- which suggests that it could fall by --. Given that UCB SA has higher upside potential than Celyad Oncology SA, analysts believe UCB SA is more attractive than Celyad Oncology SA.

UCB SA has a beta of 0.684, which suggesting that the stock is 31.623% less volatile than S&P 500. In comparison Celyad Oncology SA has a beta of 0.179, suggesting its less volatile than the S&P 500 by 82.065%.

UCB SA has a quarterly dividend of $0.79 per share corresponding to a yield of 0.53%. Celyad Oncology SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UCB SA pays 15.96% of its earnings as a dividend. Celyad Oncology SA pays out -- of its earnings as a dividend. UCB SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

UCB SA quarterly revenues are --, which are smaller than Celyad Oncology SA quarterly revenues of --. UCB SA's net income of -- is lower than Celyad Oncology SA's net income of --. Notably, UCB SA's price-to-earnings ratio is 37.32x while Celyad Oncology SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UCB SA is 7.74x versus 30.84x for Celyad Oncology SA. Usually stocks with elevated PS ratios are considered overvalued.

Galapagos NV has a net margin of -- compared to UCB SA's net margin of -286.67%. UCB SA's return on equity of 13.88% beat Galapagos NV's return on equity of -16.48%.

UCB SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Galapagos NV has an analysts' consensus of $27.63 which suggests that it could fall by -16.54%. Given that Galapagos NV has higher upside potential than UCB SA, analysts believe Galapagos NV is more attractive than UCB SA.

UCB SA has a beta of 0.684, which suggesting that the stock is 31.623% less volatile than S&P 500. In comparison Galapagos NV has a beta of 0.220, suggesting its less volatile than the S&P 500 by 77.977%.

UCB SA has a quarterly dividend of $0.79 per share corresponding to a yield of 0.53%. Galapagos NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UCB SA pays 15.96% of its earnings as a dividend. Galapagos NV pays out -- of its earnings as a dividend. UCB SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

UCB SA quarterly revenues are --, which are smaller than Galapagos NV quarterly revenues of $83.2M. UCB SA's net income of -- is lower than Galapagos NV's net income of -$238.4M. Notably, UCB SA's price-to-earnings ratio is 37.32x while Galapagos NV's PE ratio is 21.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UCB SA is 7.74x versus 6.89x for Galapagos NV. Usually stocks with elevated PS ratios are considered overvalued.

MDxHealth SA has a net margin of -- compared to UCB SA's net margin of -29.2%. UCB SA's return on equity of 13.88% beat MDxHealth SA's return on equity of -548.42%.

UCB SA has a consensus price target of --, signalling downside risk potential of --. On the other hand MDxHealth SA has an analysts' consensus of $7.0400 which suggests that it could grow by 115.95%. Given that MDxHealth SA has higher upside potential than UCB SA, analysts believe MDxHealth SA is more attractive than UCB SA.

UCB SA has a beta of 0.684, which suggesting that the stock is 31.623% less volatile than S&P 500. In comparison MDxHealth SA has a beta of -556,299.560, suggesting its less volatile than the S&P 500 by 55630055.981%.

UCB SA has a quarterly dividend of $0.79 per share corresponding to a yield of 0.53%. MDxHealth SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UCB SA pays 15.96% of its earnings as a dividend. MDxHealth SA pays out -- of its earnings as a dividend. UCB SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

UCB SA quarterly revenues are --, which are smaller than MDxHealth SA quarterly revenues of $27.4M. UCB SA's net income of -- is lower than MDxHealth SA's net income of -$8M. Notably, UCB SA's price-to-earnings ratio is 37.32x while MDxHealth SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UCB SA is 7.74x versus 1.56x for MDxHealth SA. Usually stocks with elevated PS ratios are considered overvalued.

Nyxoah SA has a net margin of -- compared to UCB SA's net margin of -1195.73%. UCB SA's return on equity of 13.88% beat Nyxoah SA's return on equity of -96.48%.

UCB SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Nyxoah SA has an analysts' consensus of $11.23 which suggests that it could grow by 120.12%. Given that Nyxoah SA has higher upside potential than UCB SA, analysts believe Nyxoah SA is more attractive than UCB SA.

UCB SA has a beta of 0.684, which suggesting that the stock is 31.623% less volatile than S&P 500. In comparison Nyxoah SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

UCB SA has a quarterly dividend of $0.79 per share corresponding to a yield of 0.53%. Nyxoah SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UCB SA pays 15.96% of its earnings as a dividend. Nyxoah SA pays out -- of its earnings as a dividend. UCB SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

UCB SA quarterly revenues are --, which are smaller than Nyxoah SA quarterly revenues of $2.3M. UCB SA's net income of -- is lower than Nyxoah SA's net income of -$27.6M. Notably, UCB SA's price-to-earnings ratio is 37.32x while Nyxoah SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UCB SA is 7.74x versus 30.26x for Nyxoah SA. Usually stocks with elevated PS ratios are considered overvalued.